医渡科技2023年度报告

(incorporated in the Cayman Islands with limited liability) Stock code Annual Report2023 2461021274449107122141148150152153154248249 202321202321202321202321 98 18814 Suite#4–210, Governors Square23 Lime Tree Bay AvenuePO Box 32311Grand Cayman KY1-1209, Cayman Islands 22 •1523 1C19100738 202321202321 1826 202321202321 183171712–1716 Maples Fund Services (Cayman) LimitedPO Box 1093, Boundary HallCricket SquareGrand Cayman KY1-1102, Cayman Islands 83One Bay East 8E1 28B1 2158 www.yidutechgroup.com 2023 客戶聚焦 業務聚焦 •以創新為驅動不斷升級迭代專業化產品矩陣，提供高品質的專業服務，以滿足核心客戶的多元化需求•大數據平台和解決方案板塊發佈新一代醫院場景智能解決方案，升級推出全病種數據庫平台，實現全院自助式創建專病庫；以及新一代數據中心YiduEywa2.0，幫助醫院實現醫療數據資產化和要素化•生命科學解決方案板塊覆蓋全球前20的MNC客戶數量達到16家。收入前20的客戶中，上市公司數量達到17家•截至2023年3月31日，集團在手訂單金額為人民幣9.16億元，同比增長45.8% •聚焦醫療智能行業，持續發力於研究，診療，公共健康三大場景•圍繞核心能力建設，推動三大場景下的多場景應用，實現場景驅動下的智能化的反覆迭代與優化 疾病聚焦 •持續聚焦重點疾病領域，包括實體腫瘤、血液、眼科、免疫、心血管•專病庫覆蓋超70個疾病領域，包含超過20個以上的癌種•公衛解決方案可覆蓋中國疾病預防控制中心定義的全部40種傳染病•以我們自主研發的糖尿病數字療法為基礎的糖尿病數字療法產品已通過美國食品藥品監督管理局和海南省藥品監督管理局審批 組織聚焦 •基於YiduCore及核心能力的複用，持續提升三大業務板塊間的協同，以提升客戶認知，業務滲透率和內部經營效率•積極與關鍵意見領袖及行業專家建立網絡，已有86名行業領導者及臨床專家出席生命科學解決方案板塊舉辦的「開心智研」直播活動，分享洞見，並吸引超過4,000名臨床研究人員參加•用於經營活動的現金淨流出同比縮窄41.9% 2023 YiduCore2023331916.545.8%22.2%41.9% YiduCoreYiduEywa2.0YiduEywa2.0YiduCore(DCT) 20233318002022 YiduCore 2023331YiduCore8341,50010,0007015 YiduCore YiduCore IIIIV2023331204 (RWD)MNCCRO10%2 MNC 40202333123 YiduCore(FDA) 202333141290%202215 2023630 2022COVID-19 2022 YiduCore2023331YiduCore834YiduCore2023331883416720 2023331804.735.0%632.417.5%448.722.2%41.9% YiduCore YiduCore YiduCore2023331YiduCore90,00010,000ICDMeSH ATC10YiduCore2023331YiduCore702023331YiduCore8341,500YiduCore1.5 YiduCore202333115CRF(CaseReport Form)202333123 YiduCoreYiduCore2.7.08.0.0AI2022 2022YiduCore 221.9202233150.1%COVID-1920233312022688834 YiduEywa2.0YiduEywa2.0 10 AI10010 RWE YiduCoreDCT20202022®DCT MNC20221120233Use of real-world evidence to support regulatory decisions onmedical devices in China and a unique opportunity to gain accelerated approval in ‘Boao Lecheng Pilot Zone’Cost Effectiveness and Resource Allocation COVID-192023331252.929.6%202333125520417420233311671541094.1%20617 202333118ADCCAR-TDCT864,000 20233318CAR-T(SOPs)SOPs 329.922.4% YiduCore 202333141290%202215 1202335014%2023150858% 202285%20232542 202220221 YiduCoreFDA 202333120 (i)(ii)YiduCore(iii)(iv)(v)(vi)(vii) (i)(ii)(iii) YiduCore(i)(ii)RWE(iii)(iv) (i)(ii)(iii) 20223311,237.235.0%2023331804.7 2022331444.950.1%2023331221.9COVID-19 2022331359.429.6%2023331252.9COVID-19 2022331424.922.4%2023331329.9 20223318.0100%2023331 2022331837.836.7%2023331530.22022202333113.28.02023 2022331252.350.1%2023331126.0(i)169.565.4(ii)77.459.37.03.8 2022331270.822.9%2023331208.7(i)160.7113.3(ii)100.488.42.72.1 2022331307.336.4%2023331195.5275.4171.5 20223317.5100%2023331 20222023331399.4274.532.3%34.1% 202333143.2%202233143.3% 202233124.7%202333117.5%2023331COVID-19 202233127.7%202333140.7% 2022331413.934.4%2023331271.6(i)234.7165.027.917.1(ii)105.934.3 202233133.5%202333133.8% 2022331337.031.2%2023331232.0(i)249.3182.599.547.6(ii)37.42.6 202233127.2%202333128.8% 2022331368.77.1%2023331342.5(i)292.4259.742.226.3(ii)32.945.5 202233129.8%202333142.6% 2022331767.417.9%2023331630.0 2022331(0.5)20233313.4 2022331766.417.5%2023331632.4 — (i)(ii) 20222023331577.0448.7 20222023331 2023331202220233313,732.13,522.0 2023331Marvelous Panda Inc.YDCapital IL.P.40.040%2023331557,748.0(i)(ii)(iii) 1414A2022102820221220 2023331EVYD Technology LimitedEVYD BVI20%55.0EVYDBVI70.1%EVYDBVI316.659.9 1420221221 2023331 2023331 2023331 20233312023331300.184.62022331141.86.620222023331 20233312022331 20233312.320223312.3 2023331284.020223311.9Marvelous Panda Inc.YD Capital I L.P. 20233311,0205371333502023331 202333153.5%30.1%2023331777.72022331982.5 331 2023331 (1)(2)(3)(4) (1)202321(2)202321(3)202321(4)202321 4448 20141292021115 (AI) 5 148 62251026 •••AI••••• • 20233313838(b)(ii)14A14A 202012252023331 (i)(ii)(iii)YiduCore 5,000,0000 (i)(ii)(iii)(iv) (i)(ii) 14A.25 20218259.99%2021825 202081860.5%202259.5%20.8%202217.7% (i)(ii)(iii) (1)99%1%(2)99%1%(3)99%1%(4)51%49%(5)(6) (7)(8)(9)(10)(11)(i)(ii)(iii) 7681 ••••••• 2020818 (a)(b)(c) 202081810 2020818 2020109202092920209292020930 2020818 (i)(ii)(iii)(iv)(v) 248266 14A 14A14A (i)14A.105(ii)14A.53(iii)14A.52 (a) (b) (c) (d)(i)(ii)(iii) (e) (i)(ii)(iii)(iv)(v)(vi) (i)(ii)(iii)(iv) (v) 85.210.6%274.634.1% 5% (i)IT(ii) 55.09.7%212.737.5% 5% 12 16 27 0.5 20233312023331 2023331 1522840 2023331 3.2514 30109120 419 6.141 8.10 13.2013.2113.22 2023630 (1)(2)202321(3)202321(4)202321(5)202321 39 Credit Suisse First BostonCredit Suisse2005720073Global Infrastructure Partners LLP2006112007620077200812(Deutsche Bank AG)2011120122Credit Suisse First BostonGlobal Infrastructure Partners LLP20193 20121020057 39202322015102018320191— 20151020156201510UCWeb201352015620087